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Summary
LV mass by CMR is a powerful predictor of adverse car-
diovascular outcomes in patients treated with
anthracyclines.
Background
Late gadolinium enhancement (LGE) is a predictor of
adverse outcomes in patients. However, limited data
exist on the role of LGE, the characteristic CMR find-
ings, and the prognostic variables in patients who
develop a cardiomyopathy after treatment with
anthracyclines.
Methods
LGE-CMR imaging was performed in patients with stage
B and C heart failure after anthracycline-based che-
motherapy. We assessed the association between CMR,
EKG, echocardiographic, serum, and clinical variables
with adverse outcomes (cardiovascular death and admis-
sion for heart failure).
Results
We performed a clinically-indicated CMR study on 50
patients (52% male, mean age of 49 ± 16 years, anthracy-
cline dose of 286 ± 89 mg/m2, and ejection fraction of 38
± 9%) with AC-mediated cardiomyopathy. Patients pre-
sented a median of 45 months after chemotherapy and
were followed for a median period of 28 months. LGE
was an uncommon finding (3 patients, 6%). There was a
strong inverse association between anthracycline dose
and indexed left ventricular mass by CMR (r = -.75, p <
0.001, Figure 1). In univariate analysis, indexed LV-mass
by CMR demonstrated the strongest unadjusted associa-
tion with adverse events (hazard ratio: 0.75, chi-squared
26.2, p < 0.001). In a multivariable model, indexed LV-
mass demonstrated the strongest association with the
primary outcome (Figure 2).
Conclusions
Residual LV-mass measured by CMR is a powerful pre-
dictor of subsequent adverse cardiovascular events in
patients with anthracycline-induced cardiotoxicity.
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